跳至主要内容
临床试验/NCT03682809
NCT03682809已完成4 期

Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort

University of Alabama at Birmingham3 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2018年11月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
46
试验地点
3
主要终点
Contact Lens Symptoms

研究概览

简要总结

Clinicians commonly use artificial tears off label for treating contact lens (CL) discomfort and the dry eye associated with CLs because new artificial tear formulations have the potential to outperform the available CL rewetting drops. While off-label, McDonald et al. have previously shown that using a common artificial tear, Systane Ultra, before and after CL use is an effective means for treating daily disposable CL wears who have CL discomfort. Recently, a new formulation of artificial tears, Systane Complete, was released to the market. Systane Complete is a unique formulation that has combined elements from both Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for evaporative dry eye) to create an artificial tear with an indication for aqueous deficient, evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the goal of this study is to determine in a randomized clinical trial if Systane Complete is able to effectively improve the symptoms of patients who have CL discomfort.

详细描述

Soft contact lenses (CL) are the most common CL modality with over 140 million users world. Despite many improvements in CL materials and solutions, the advent of daily disposable CLs, and the addition of rewetting drops to improve CL comfort, research has shown that between 21% to 64% of CL wearers permanently discontinue CL use because of eye discomfort. Contact Lens Discomfort (CLD) as defined by the Tear Film and Ocular Surface Society (TFOS) "is a condition characterized by episodic or persistent adverse ocular sensations related to lens wear, either with or without visual disturbance, resulting from reduced compatibility between the CL and the eye's environment, which can lead to decreased wearing time and discontinuation of CL wear." TFOS further states that CLD is a multifactorial condition that stems from both CL (e.g., material design, fit, care system) and environmental factors (patient factors, medication compliance, external environmental factors, ocular environment). While environmental factors related to the patient such as age and sex are inherent, rewetting drops or artificial tears can be used to treat tear film deficiencies associated with CLD. The U.S. Food & Drug Administration (FDA) defines rewetting/lubricating drops as "an in-eye solution for use with CLs" that contains "one or more active ingredients (e.g., ophthalmic demulcents) in sufficient concentration to alleviate symptoms of discomfort from CL wear by physical means." Clinicians also commonly use artificial tears off label for treating CLD and the dry eye associated with CLs because artificial tear formulations have the potential to outperform CL rewetting drops. The FDA separately classifies artificial tears as topical drops that contain specific types of demulcents or emollients. While off-label, McDonald et al. have previously shown that using a common artificial tear, Systane Ultra, before and after CL use is an effective means for treating daily disposable CL wears who have CLD. Recently, a new formulation of artificial tears, Systane Complete, was released to the market. Systane Complete is a unique formulation that has combined elements from both Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for evaporative dry eye) to create an artificial tear with an indication for aqueous deficient, evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the Research Goal of this study is to determine in a randomized clinical trial if Systane Complete is able to effectively improve the symptoms of CLD suffers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

The patients who are randomized to Systane Complete will be masked to the brand of the artificial tears.

There will be a masked examiner who does not know the subject's study group.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Self-reported contact lens discomfort
  • Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores ≥ 12
  • Daily disposable contact lens wearer
  • Best-corrected visual acuity of 20/30 or better

排除标准

  • All other contact lens types (e.g., currently wearing two week or monthly replacement contact lenses or hard contact lenses)
  • Non-compliant daily disposable contact lens wearers (must regularly replace contact lenses daily)
  • Systemic health conditions known to alter tear film physiology
  • History of ocular surgery within the past 12 months
  • History of severe ocular trauma, active ocular infection, or inflammation
  • Currently using Accutane or eye medications
  • Pregnant or breast feeding

研究组 & 干预措施

Systane Complete

Experimental

Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.

干预措施: Systane Complete (Drug)

结局指标

主要结局

Contact Lens Symptoms

时间窗: Baseline through 2 Weeks

Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.

次要结局

  • End of Day Eye Comfort(Baseline through 2 Weeks)
  • Corneal Staining(Baseline through 2 Weeks)
  • Schirmer's I Test Without Anesthetic(Baseline through 2 Weeks)
  • Tear Break-Up Time (TBUT)(Baseline through 2 Weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew Pucker

Assistant Professor

University of Alabama at Birmingham

研究点 (3)

Loading locations...

相似试验